SG156666A1 - Vaccines against japanese encephalitis virus and west nile virus - Google Patents

Vaccines against japanese encephalitis virus and west nile virus

Info

Publication number
SG156666A1
SG156666A1 SG200906992-3A SG2009069923A SG156666A1 SG 156666 A1 SG156666 A1 SG 156666A1 SG 2009069923 A SG2009069923 A SG 2009069923A SG 156666 A1 SG156666 A1 SG 156666A1
Authority
SG
Singapore
Prior art keywords
virus
west nile
japanese encephalitis
vaccines against
against japanese
Prior art date
Application number
SG200906992-3A
Other languages
English (en)
Inventor
Farshad Guirakhoo
Jian Liu
John A Catalan
Thomas P Monath
Konstantin V Pugachev
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of SG156666A1 publication Critical patent/SG156666A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG200906992-3A 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus SG156666A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62046604P 2004-10-20 2004-10-20
US62094804P 2004-10-21 2004-10-21
US67441505P 2005-04-24 2005-04-24
US67454605P 2005-04-25 2005-04-25
US71892305P 2005-09-19 2005-09-19

Publications (1)

Publication Number Publication Date
SG156666A1 true SG156666A1 (en) 2009-11-26

Family

ID=36203650

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200906992-3A SG156666A1 (en) 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus

Country Status (13)

Country Link
US (2) US8029802B2 (enExample)
EP (1) EP1809325B1 (enExample)
JP (1) JP4993301B2 (enExample)
KR (1) KR101501162B1 (enExample)
AU (1) AU2005295438B2 (enExample)
CA (1) CA2584228C (enExample)
EA (1) EA015907B1 (enExample)
IL (1) IL182453A0 (enExample)
MY (1) MY148075A (enExample)
NO (1) NO20071924L (enExample)
NZ (1) NZ584079A (enExample)
SG (1) SG156666A1 (enExample)
WO (1) WO2006044857A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322026B2 (en) 2001-06-01 2008-03-13 Acambis Inc. Chimeric flavivirus vectors
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
MXPA05005140A (es) 2002-11-15 2005-08-19 Acambis Inc Vacuna contra el virus del nilo occidental.
KR101501162B1 (ko) 2004-10-20 2015-03-16 사노피 파스테르 바이오로직스, 엘엘씨 일본 뇌염 바이러스 및 웨스트 나일 바이러스에 대한 백신
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
DK2601969T3 (en) 2006-09-29 2016-04-18 Takeda Vaccines Inc Norovirus vaccine formulations
US9132184B2 (en) 2006-11-07 2015-09-15 Sanofi Pasteur Biologics, Llc Stabilization of vaccines by lyophilization
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG184733A1 (en) 2007-09-18 2012-10-30 Ligocyte Pharmaceuticals Inc Method of conferring a protective immune response to norovirus
BRPI0913012B1 (pt) * 2008-04-30 2021-12-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos
CA2733589C (en) 2008-08-08 2021-07-13 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
AU2009313714B2 (en) * 2008-11-17 2016-05-19 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
JP5848243B2 (ja) 2009-06-01 2016-01-27 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対する免疫原性組成物
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
ES2524975T3 (es) 2009-07-31 2014-12-16 Ge Healthcare Bio-Sciences Corp. Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células
WO2011119716A2 (en) * 2010-03-24 2011-09-29 Research Development Foundation Flavivirus host range mutations and uses thereof
CN101926989A (zh) * 2010-06-29 2010-12-29 西北农林科技大学 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
US8889148B2 (en) 2010-07-01 2014-11-18 Research Development Foundation Flavivirus host-range mutations and uses thereof
DK3299030T3 (da) 2011-07-11 2022-09-05 Takeda Vaccines Inc Parenterale norovirus-vaccineformuleringer
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP3010536A4 (en) 2013-06-21 2016-11-30 Merck Sharp & Dohme DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS FOR USE THEREOF
EP3013852B1 (en) * 2013-06-26 2019-06-19 The University of North Carolina at Chapel Hill Compositions for dengue virus vaccines and their use
WO2016079560A1 (en) * 2014-11-21 2016-05-26 Institut Pasteur A live and attenuated japanese encephalitis virus comprising a mutated m protein
SG11201704942QA (en) 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
CA2992531C (en) * 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
CA3129482A1 (en) * 2019-03-28 2020-10-01 Nathalie PARDIGON A live and attenuated flavivirus comprising a mutated m protein
WO2024254552A1 (en) * 2023-06-08 2024-12-12 Modernatx, Inc. Stabilized flavivirus vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6589533B1 (en) 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
RU2208635C2 (ru) 1997-10-08 2003-07-20 ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2002081753A1 (en) 2001-04-04 2002-10-17 Advanced Research & Technology Institute Method for identifying and characterizing individual dna molecules
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
WO2003060088A2 (en) 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
MXPA05005140A (es) * 2002-11-15 2005-08-19 Acambis Inc Vacuna contra el virus del nilo occidental.
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
KR101501162B1 (ko) 2004-10-20 2015-03-16 사노피 파스테르 바이오로직스, 엘엘씨 일본 뇌염 바이러스 및 웨스트 나일 바이러스에 대한 백신
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines

Also Published As

Publication number Publication date
MY148075A (en) 2013-02-28
CA2584228A1 (en) 2006-04-27
AU2005295438A1 (en) 2006-04-27
EP1809325A2 (en) 2007-07-25
EP1809325A4 (en) 2009-07-22
AU2005295438B2 (en) 2012-07-05
EA200700904A1 (ru) 2007-12-28
NZ584079A (en) 2011-10-28
KR20070072597A (ko) 2007-07-04
CA2584228C (en) 2015-05-05
WO2006044857A3 (en) 2006-08-10
US20070269458A1 (en) 2007-11-22
JP4993301B2 (ja) 2012-08-08
EP1809325B1 (en) 2013-11-20
US8691550B2 (en) 2014-04-08
HK1106723A1 (en) 2008-03-20
WO2006044857A2 (en) 2006-04-27
US8029802B2 (en) 2011-10-04
EA015907B1 (ru) 2011-12-30
KR101501162B1 (ko) 2015-03-16
NO20071924L (no) 2007-07-17
JP2008520187A (ja) 2008-06-19
US20120201852A1 (en) 2012-08-09
IL182453A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
IL202978A0 (en) West nile virus vaccine
WO2003101397A3 (en) Tetravalent dengue vaccines
WO2005082020A3 (en) Flavivirus vaccines
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
WO2007030810A3 (en) Multiparameter whole blood monitor and method
SG165155A1 (en) Novel flavivirus antigens
WO2005011592A3 (en) Substituted indazole-o-glucosides
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
TW200738270A (en) Method of treating depression using a TNFα antibody
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
MX2010004374A (es) Armazones proteinicos.
WO2006023081A3 (en) Ceramics, and methods of making and using the same
GB2435590A (en) An interleaver and associated methods
WO2006026470A3 (en) Hiv immunostimulatory compositions
WO2006076003A3 (en) Vaccinia virus strains
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
WO2004091524A3 (en) Respiratory virus vaccines
NO20065115L (no) Cellulaer tillatende faktor for virus, og anvendelse derav
PL1833508T3 (pl) Szczepy świńskiego wirusa zespołu rozrodczo-oddechowego i ich kompozycje
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2003060088A3 (en) Viral vaccine production method
WO2006121466A3 (en) Hcv inhibitors